Why is Mankind Pharma falling/rising?

As of 17-Jul, Mankind Pharma Ltd's stock is currently priced at 2,630.40, reflecting an increase of 6.85 (0.26%). The stock has shown a positive trend, gaining after two consecutive days of decline. It is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bullish momentum. Over the past week, the stock has risen by 3.42%, significantly outperforming the Sensex, which has declined by 1.12%. Additionally, the stock has delivered a remarkable return of 24.22% over the past year, far exceeding the market's return of 1.91%. However, there has been a notable decrease in investor participation, with delivery volume falling by 39.23% compared to the 5-day average. Despite this, the company demonstrates strong fundamentals, including a high return on equity of 19.25%, a low debt-to-equity ratio, and healthy long-term growth in operating profit.
In the broader market context, Mankind Pharma's recent performance stands in stark contrast to the benchmark, as it has achieved a 3.42% increase over the past week while the Sensex has declined. This divergence highlights the stock's resilience and market-beating performance, particularly over the last year. The presence of high institutional holdings at 24.4% suggests that knowledgeable investors are confident in the company's prospects, which may contribute to the stock's upward movement. Overall, while the stock is experiencing a positive trend, the decline in delivery volume could indicate a potential concern regarding investor interest moving forward.